Littérature scientifique sur le sujet « Dopamine type I receptor »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Dopamine type I receptor ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Dopamine type I receptor"
Shariati, G. H., G. Ahangari, M. R. Asadi, F. Poyafard et H. R. Ahmadkhaniha. « Dopamine Receptor Gene Expression Changes in Peripheral Blood Mononuclear Cells from Schizophrenic Patients Treated with Haloperidol and Olanzapine ». European Journal of Inflammation 7, no 2 (mai 2009) : 71–76. http://dx.doi.org/10.1177/1721727x0900700203.
Texte intégralSarkar, D. K., K. Chaturvedi, S. Oomizu, N. I. Boyadjieva et C. P. Chen. « Dopamine, Dopamine D2 Receptor Short Isoform, Transforming Growth Factor (TGF)-β1, and TGF-β Type II Receptor Interact to Inhibit the Growth of Pituitary Lactotropes ». Endocrinology 146, no 10 (1 octobre 2005) : 4179–88. http://dx.doi.org/10.1210/en.2005-0430.
Texte intégralPeiser, Christian, Marcello Trevisani, David A. Groneberg, Q. Thai Dinh, Doerthe Lencer, Silvia Amadesi, Barbara Maggiore, Selena Harrison, Pierangelo Geppetti et Axel Fischer. « Dopamine type 2 receptor expression and function in rodent sensory neurons projecting to the airways ». American Journal of Physiology-Lung Cellular and Molecular Physiology 289, no 1 (juillet 2005) : L153—L158. http://dx.doi.org/10.1152/ajplung.00222.2004.
Texte intégralMyslivecek, Jaromir. « Dopamine and Dopamine-Related Ligands Can Bind Not Only to Dopamine Receptors ». Life 12, no 5 (19 avril 2022) : 606. http://dx.doi.org/10.3390/life12050606.
Texte intégralHelms, My N., Xi-Juan Chen, Semra Ramosevac, Douglas C. Eaton et Lucky Jain. « Dopamine regulation of amiloride-sensitive sodium channels in lung cells ». American Journal of Physiology-Lung Cellular and Molecular Physiology 290, no 4 (avril 2006) : L710—L722. http://dx.doi.org/10.1152/ajplung.00486.2004.
Texte intégralDing, Guoliang, Rob F. Wiegerinck, Ming Shen, Anca Cojoc, Carlo M. Zeidenweber et Mary B. Wagner. « Dopamine increases L-type calcium current more in newborn than adult rabbit cardiomyocytes via D1 and β2 receptors ». American Journal of Physiology-Heart and Circulatory Physiology 294, no 5 (mai 2008) : H2327—H2335. http://dx.doi.org/10.1152/ajpheart.00993.2007.
Texte intégralMORA-FERRER, CARLOS, et VOLKER GANGLUFF. « D2-dopamine receptor blockade impairs motion detection in goldfish ». Visual Neuroscience 17, no 2 (mars 2000) : 177–86. http://dx.doi.org/10.1017/s0952523800171196.
Texte intégralHayashida, Yuki, et Andrew T. Ishida. « Dopamine Receptor Activation Can Reduce Voltage-Gated Na+ Current by Modulating Both Entry Into and Recovery From Inactivation ». Journal of Neurophysiology 92, no 5 (novembre 2004) : 3134–41. http://dx.doi.org/10.1152/jn.00526.2004.
Texte intégralPfeiffer-Linn, C., et E. M. Lasater. « Dopamine modulates in a differential fashion T- and L-type calcium currents in bass retinal horizontal cells. » Journal of General Physiology 102, no 2 (1 août 1993) : 277–94. http://dx.doi.org/10.1085/jgp.102.2.277.
Texte intégralMilienne-Petiot, Morgane, Lucianne Groenink, Arpi Minassian et Jared W. Young. « Blockade of dopamine D1-family receptors attenuates the mania-like hyperactive, risk-preferring, and high motivation behavioral profile of mice with low dopamine transporter levels ». Journal of Psychopharmacology 31, no 10 (27 septembre 2017) : 1334–46. http://dx.doi.org/10.1177/0269881117731162.
Texte intégralThèses sur le sujet "Dopamine type I receptor"
Hatcher-Solis, Candice N. « PHARMACOLOGICAL IMPLICATIONS OF ADENOSINE 2A RECEPTOR- DOPAMINE TYPE 2 RECEPTOR HETEROMERIZATION ». VCU Scholars Compass, 2016. http://scholarscompass.vcu.edu/etd/4458.
Texte intégralZANINOVICH, OREL ANTHONY. « THE CLONING OF AN INDR-TYPE DOPAMINE RECEPTOR IN MANDUCA SEXTA ». Thesis, The University of Arizona, 2008. http://hdl.handle.net/10150/192256.
Texte intégralMann, Miranda Jane. « A neuropsychological investigation of dopamine receptor 4 differences among attention deficit hyperactivity disorder-combined type and control children / ». Digital version accessible at:, 2000. http://wwwlib.umi.com/cr/utexas/main.
Texte intégralGorji, Hassan. « Role of adenylyl cyclase type 5 in the regulation of the dopamine D3 receptor phosphorylation ». Thesis, University of Ottawa (Canada), 2006. http://hdl.handle.net/10393/27364.
Texte intégralMaier, Annette Louise. « Comparative regional ontogeny of dopamine D₁ receptor binding and mRNA expression in pre- and postnatal rat brain / ». Zürich, 1994. http://e-collection.ethbib.ethz.ch/show?type=diss&nr=10902.
Texte intégralEtchepare, Laetitia. « Role of glutamate N-Methyl-D-Aspartate receptor surface trafficking in the firing pattern of midbrain dopaminergic neurons ». Thesis, Bordeaux, 2017. http://www.theses.fr/2017BORD0849/document.
Texte intégralMidbrain dopaminergic (DA) neurons play several key functions in the brain such as the processing of salient information but are also associated with the emergence of pathologies including Parkinson’s disease and drug addiction. Because these processes have in common to modify the firing activity of midbrain DA neurons, it is of crucial importance to understand the mechanisms underlying this activity. Among the various ions channels and receptors involved in the generation of the firing activity of midbrain DA neurons, glutamate N-methyl-D-aspartate receptors (NMDAR) and calciumdependent potassium SK channels strongly modulate the firing pattern and functionally interact in several neuronal types including DA neurons. However, the mechanisms by which they regulate the firing pattern are poorly understood. Since the functional coupling between NMDAR and SK channels depends on their relative membrane distribution, we hypothesized that the lateral diffusion of NMDAR, which regulates the surface localization of the receptor, could play a role in the firing pattern of midbrain DA neurons through the modulation of SK channel function. We showed first that membrane NMDAR was highly mobile in cultured DA neurons. Alteration of its surface trafficking by a crosslink with NMDAR antibodies profoundly modified the regularity of the firing pattern of DA neurons in midbrain slices, whereas pharmacological blockade of NMDAR did not affect it. Furthermore, a SK channel blocker, which induces a similar change in the firing regularity in control conditions, was less effective when NMDAR surface trafficking was altered. Taken together, these results demonstrate that NMDAR surface dynamics modulate the firing pattern of midbrain DA neurons by regulating SK channel function
Roberts-Crowley, Mandy L. « Modulation of Cav1.3 L-Type Calcium Channels by Arachidonic Acid and Muscarinic M1 Receptors : A Dissertation ». eScholarship@UMMS, 2007. https://escholarship.umassmed.edu/gsbs_diss/348.
Texte intégralLucas, Guillaume. « Etude in vivo des modalités d'intervention de la sérotonine et des récepteurs sérotoninergiques de type 5-HT/2A/2C, 5-HT3 et 5-HT4 dans le contrôle de la transmission dopaminergique nigro-striée et mésoaccumbale chez le rat ». Bordeaux 2, 1999. http://www.theses.fr/1999BOR28692.
Texte intégralHegron, Alan. « Implication des récepteurs de la mélatonine dans les troubles neurologiques et le diabète de type 2 et identification de régions clés du récepteur MT1 responsables de sa sélectivité fonctionnelle ». Thesis, Université Paris-Saclay (ComUE), 2018. http://www.theses.fr/2018SACLS555/document.
Texte intégralMelatonin is a neurohormone mainly released from the pineal gland in a circadian manner acting through two G protein-coupled receptors (GPCRs) called MT1 and MT2. Melatonin regulates many important physiological functions. Regulation of dopamine (DA) and glucose levels are two of them but how they do this is not clear.Extracellular DA levels are mainly regulated by its transporter (DAT) which mediates DA re-uptake into presynaptic nerve termini to prevent DA receptor hyperactivation in the presynaptic cleft. Consequently, we verified the role of DAT in the regulation of the DA system by melatonin. We showed that MT1 and MT2, by interacting with the immature non-glycosylated form of DAT retain DAT in the endoplasmic reticulum thus regulating DAT cell surface expression and DA reuptake. Consistently, mice with targeted deletion of MT1 and MT2 show markedly enhanced DA uptake in striatal synaptosomes and decreased amphetamine-induced locomotor activity. Collectively, we revealed here a molecular link between the melatonin and DA systems, which is based on the formation of a molecular complex between melatonin receptors and DAT.To better understand the role of melatonin on the regulation of glucose levels, we studied the involvement of genetic variants of MT2 in the development of type 2 diabetes (T2D). Previous studies showed that natural loss-of-function variants of MT2 associate with T2D risk. To determine more precisely the defective properties linked to T2D risk we monitored spontaneous and melatonin-induced activation of different signaling pathways by 40 MT2 variants. We show that defects in melatonin-induced Gαi and Gαz activation and spontaneous βarrestin-2 recruitment are most significantly associated to T2D risk. Experimental results correlated well with those predicted by evolutionary lineage analysis. This work will help to propose personalized treatments for MT2 variant carriers to recover their defective responses.Sequencing of 9393 individuals resulted in the identification of 32 natural MT1 variants. MT1 wild-type and variants were functionally characterized in bioluminescence resonance energy transfer (BRET) assays. We showed that MT1 activates Gαi/o, Gα12 and Gα15 proteins and recruits βarrestin-2. Analyzes of results by non-linear matrix factorization revealed the existence of 5 clusters characterized by different signaling profiles. Computational homology modeling of the 3D model of MT1 helped to determine the impact of each variant on receptor activation and interaction with G proteins and βarrestin-2. Collectively, our data illustrate that natural variants are powerful tools to understand the molecular basis of GPCR function. Overall, this work contributes to our understanding of the function of melatonin receptors and highlights their importance in the regulation of the DA system and glucose homeostasis. Our results will open new, personalized therapeutic options for patient suffering from a defective DA system or T2D
Thirtamara, Rajamani Keerthi Krishnan. « Animal Models of Drug Addiction and Autism Spectrum Disorders ». The Ohio State University, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=osu1386011455.
Texte intégralLivres sur le sujet "Dopamine type I receptor"
Tupala, Erkki. Dopamine receptors and transporters in type 1 and 2 alcoholism measured with postmortem human whole hemisphere autoradiography. Kuopio : University of Kuopio, 2001.
Trouver le texte intégralTiberi, Mario. Dopamine receptor technologies. New York, NY : Humana Press, 2015.
Trouver le texte intégralTiberi, Mario, dir. Dopamine Receptor Technologies. New York, NY : Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2196-6.
Texte intégralDonthamsetti, Prashant Chandra. Dissecting Dopamine D2 Receptor Signaling. [New York, N.Y.?] : [publisher not identified], 2015.
Trouver le texte intégralL, Waddington John, dir. D1:D2 dopamine receptor interactions. London : Academic Press, 1993.
Trouver le texte intégralBoileau, Isabelle, et Ginetta Collo, dir. Therapeutic Applications of Dopamine D3 Receptor Function. Cham : Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-23058-5.
Texte intégralKnapp, Mark. Development of dopamine receptor expressing adenoviral vectors. Ottawa : National Library of Canada, 1997.
Trouver le texte intégralR, Demirdamar, et Jenner Peter 1946-, dir. Dopamine receptor subtypes : From basic science to clinical application. Amsterdam : IOS Press, 1998.
Trouver le texte intégralRay, Avi Andrew. SH3 binding domains in the dopamine D(3) receptor. Ottawa : National Library of Canada, 1999.
Trouver le texte intégralZawarynski, Paul. Dopamine D2 receptor monomers, dimers and higher order oligomers. Ottawa : National Library of Canada, 1998.
Trouver le texte intégralChapitres de livres sur le sujet "Dopamine type I receptor"
Turco, Raymond. « Dopamine Receptor ». Dans Encyclopedia of Animal Cognition and Behavior, 1–5. Cham : Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-47829-6_1256-1.
Texte intégralTurco, Raymond. « Dopamine Receptor ». Dans Encyclopedia of Animal Cognition and Behavior, 2120–25. Cham : Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-319-55065-7_1256.
Texte intégralFuxe, Kjell, Daniel Marcellino, Diego Guidolin, Amina Woods et Luigi Agnati. « Dopamine Receptor Oligomerization ». Dans The Dopamine Receptors, 255–80. Totowa, NJ : Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_10.
Texte intégralHazelwood, Lisa A., R. Benjamin Free et David R. Sibley. « Dopamine Receptor-Interacting Proteins ». Dans The Dopamine Receptors, 219–54. Totowa, NJ : Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_9.
Texte intégralDeth, Richard C. « The Dopamine D4 Receptor ». Dans Molecular Origins of Human Attention, 23–36. Boston, MA : Springer US, 2003. http://dx.doi.org/10.1007/978-1-4615-0335-4_4.
Texte intégralRichtand, Neil M., Laurel M. Pritchard et Lique M. Coolen. « Dopamine Receptor Alternative Splicing ». Dans Dopamine and Glutamate in Psychiatric Disorders, 45–61. Totowa, NJ : Humana Press, 2005. http://dx.doi.org/10.1007/978-1-59259-852-6_2.
Texte intégralCivelli, Olivier, James Bunzow, Paul Albert, Hubert H. M. Van Tol et David Grandy. « The Dopamine D2 Receptor ». Dans Molecular Biology of G-Protein-Coupled Receptors, 160–69. Boston, MA : Birkhäuser Boston, 1992. http://dx.doi.org/10.1007/978-1-4684-6772-7_7.
Texte intégralCepeda, Carlos, Véronique M. André, Emily L. Jocoy et Michael S. Levine. « Dopamine Receptor Modulation of Glutamatergic Neurotransmission ». Dans The Dopamine Receptors, 281–302. Totowa, NJ : Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_11.
Texte intégralLee, Frankie H. F., et Albert H. C. Wong. « Dopamine Receptor Genetics in Neuropsychiatric Disorders ». Dans The Dopamine Receptors, 585–632. Totowa, NJ : Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_19.
Texte intégralMoreira, Irina S., Lei Shi, Zachary Freyberg, Spencer S. Ericksen, Harel Weinstein et Jonathan A. Javitch. « Structural Basis of Dopamine Receptor Activation ». Dans The Dopamine Receptors, 47–73. Totowa, NJ : Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-333-6_3.
Texte intégralActes de conférences sur le sujet "Dopamine type I receptor"
Kamasak, Mustafa E., Charles A. Bouman, Bradley T. Christian et Evan D. Morris. « Imaging D2-Dopamine Receptor using PET ». Dans 2007 IEEE 15th Signal Processing and Communications Applications. IEEE, 2007. http://dx.doi.org/10.1109/siu.2007.4298698.
Texte intégralMoritz, Amy E., Nora S. Madaras, Kirsten K. Snyder, Noelia M. Boldizsar, Raphael Haider, Julia Drube, Arun K. Ghosh, John JG Tesmer, Carsten Hoffmann et David R. Sibley. « Regulation of Dopamine Receptor Subtypes by G Protein-Coupled Receptor Kinase Isoforms ». Dans ASPET 2024 Annual Meeting Abstract. American Society for Pharmacology and Experimental Therapeutics, 2024. http://dx.doi.org/10.1124/jpet.159.988010.
Texte intégralLiu, X., J. Guan, F. Tao et B. Mao. « Acupuncture Zusanli Regulate COPD Inflammation Through Dopamine D2 Receptor ». Dans American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4755.
Texte intégralHarrison, J. M., I. Nir, M. Rubinstein, M. J. Low, D. K. Grandy et P. M. Iuvone. « Retinal Function in Dopamine D4 Receptor Knockout (D4KO) Mice ». Dans Vision Science and its Applications. Washington, D.C. : OSA, 2000. http://dx.doi.org/10.1364/vsia.2000.fd2.
Texte intégralJavadi, Arman, Nicholas Forsythe, Alaa Refaat, Jessica-Ann Weir, Hajrah Khawaja, David Waugh, Rohinton Tarapore, Joshua E. Allen, Patrick Johnston et Sandra Van Schaeybroeck. « Abstract 3448 : Targeting the dopamine receptor 2 inBRAFmutant colorectal cancer ». Dans Proceedings : AACR Annual Meeting 2018 ; April 14-18, 2018 ; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-3448.
Texte intégralUysal, Mehmet Atilla, Ulgen Sever et Sacide Pehlivan. « The dopamine receptor D4 VNTR 48bp gene variant in nicotine addiction ». Dans ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.oa1486.
Texte intégralRaghuraman, Gayatri, Nanduri R. Prabhakar et Ganesh K. Kumar. « Dopamine D1 Receptor Signaling Mediates Altered GABA Synthesis By Intermittent Hypoxia ». Dans American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a6630.
Texte intégralBlake, Keyana, Basant Hens et Anthony J. Baucum. « Investigating the role of spinophilin in mediating Dopamine D2 Receptor Activity ». Dans ASPET 2024 Annual Meeting Abstract. American Society for Pharmacology and Experimental Therapeutics, 2024. http://dx.doi.org/10.1124/jpet.321.940880.
Texte intégralWen, Ruojian, Xiaoqing Chen, Dan Huang, Minjie Chen et Yuwei Liu. « Sleep Deprivation Increased Dopamine D2 Receptor Expression through Downregulation of miR-9 ». Dans 2015 7th International Conference on Information Technology in Medicine and Education (ITME). IEEE, 2015. http://dx.doi.org/10.1109/itme.2015.122.
Texte intégralMadaras, Nora S., Michele L. Rankin, R. Benjamin Free, Raphael Haider, Julia Drube, Arun K. Ghosh, John JG Tesmer, Carsten Hoffmann, David R. Sibley et Amy E. Moritz. « Delineation of the G Protein-Coupled Receptor Kinase Phosphorylation Sites Within the D1 Dopamine Receptor and Their Role in Regulating Receptor Function ». Dans ASPET 2023 Annual Meeting Abstracts. American Society for Pharmacology and Experimental Therapeutics, 2023. http://dx.doi.org/10.1124/jpet.122.154110.
Texte intégralRapports d'organisations sur le sujet "Dopamine type I receptor"
Dr. Jogeshwar Mukherjee. Development of dopamine receptor radiopharmaceuticals for the study of neurological and psychiatric disorders. Office of Scientific and Technical Information (OSTI), janvier 2009. http://dx.doi.org/10.2172/944919.
Texte intégralMukherjee, J. Development of dopamine receptor radiopharmaceuticals for the study of neurological and psychiatric disorders. Progress report 1994--1997. Office of Scientific and Technical Information (OSTI), août 1999. http://dx.doi.org/10.2172/764610.
Texte intégralReiss, Michael. Type I Receptor Kinase Inhibitors - A Novel Treatment for Breast Cancer. Fort Belvoir, VA : Defense Technical Information Center, juin 2002. http://dx.doi.org/10.21236/ada408030.
Texte intégralFagan, Dedra. Type-I Insulin-Like Growth Factor Receptor (IGF1R)-Estrogen Receptor (ER) Crosstalk Contributes to Antiestrogen Therapy Resistance in Breast Cancer Cells. Fort Belvoir, VA : Defense Technical Information Center, février 2013. http://dx.doi.org/10.21236/ada575846.
Texte intégralReise, Michael. TGF-beta Type I Receptor Kinase Inhibitors - A Novel Treatment for Breast Cancer. Fort Belvoir, VA : Defense Technical Information Center, juin 2003. http://dx.doi.org/10.21236/ada416442.
Texte intégralRausch, Matthew. Enhancement of Dendritic Cell-Based Immunotherapy Using a Small Molecule TGF-beta Receptor Type I Kinase Inhibitor. Fort Belvoir, VA : Defense Technical Information Center, juin 2008. http://dx.doi.org/10.21236/ada487435.
Texte intégralPlymate, Stephen R. Therapy of Prostate Cancer Using a Human Antibody Targeting the Type 1 Insulin-Like Growth Factor Receptor (IGF-IR). Fort Belvoir, VA : Defense Technical Information Center, septembre 2009. http://dx.doi.org/10.21236/ada524529.
Texte intégralThomas, Tania, S. Shappell, S. Kasper, R. A. Serra et H. L. Moses. The Development and Characterization of a Transgenic Mouse Model Over-Expressing a Truncated TGF(Beta) Type II Receptor in the Prostate. Fort Belvoir, VA : Defense Technical Information Center, juillet 2000. http://dx.doi.org/10.21236/ada390670.
Texte intégralZhuo, Chuanjun, Hongjun Tian, Lina Wang, Xiangyang Gao, Li Ding et Ming Liu. Comparative safety of glucagon like peptide‑1 receptor agonists in patients with type 2 diabetes : a network meta-analysis of cardiovascular outcome trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, août 2020. http://dx.doi.org/10.37766/inplasy2020.8.0122.
Texte intégralDeo, Salil, David McAllister, Naveed Sattar et Jill Pell. The time-varying cardiovascular benefits of glucagon like peptide-1 agonist (GLP-RA)therapy in patients with type 2 diabetes mellitus : A meta-analysis of multinational randomized trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, juillet 2021. http://dx.doi.org/10.37766/inplasy2021.7.0097.
Texte intégral